Physician profile
Paul Tebbe
NPI 1235139973
$1,429.25
in general payments reported to CMS, 2019-2025
20 companies · $320 in 2025
The $320 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $34.44 · 2021: $158 · 2022: $235 · 2023: $227 · 2024: $280 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $293.25 | 2022-2025 | Azstarys |
| Pfizer INC. | $192.55 | 2019-2024 | |
| Glaxosmithkline, LLC. | $134.51 | 2019-2025 | Pediarix, Bexsero, Menveo |
| Merck Sharp & Dohme LLC | $104.45 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi-Aventis U.S. LLC | $85.50 | 2024-2025 | |
| Tris Pharma INC | $78.79 | 2019-2022 | |
| Cranial Technologies, INC | $75.96 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $62.92 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $60.36 | 2024 | |
| Supernus Pharmaceuticals, INC. | $57.16 | 2022-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $46.71 | 2020-2021 | |
| Alk-Abello, INC | $43.12 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $34.82 | 2023 | Flumist Quadrivalent |
| Neos Therapeutics, LP | $30.10 | 2020-2022 | |
| Sanofi Pasteur INC. | $29.25 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $23.13 | 2025 | Alvesco |
| Vertical Pharmaceuticals, LLC | $20.92 | 2024 | Relexxii |
| Novo Nordisk INC | $19.23 | 2025 | Wegovy |
| Kaleo, INC. | $19.04 | 2022 | |
| Seqirus USA INC | $17.48 | 2025 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Tebbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.